Efficacy of targeted drugs for metastatic non-clear cell renal cell carcinoma:a Meta-analysis
10.3969/j.issn.1009-8291.2023.05.006
- VernacularTitle:靶向治疗药物在转移性非透明细胞肾癌患者中应用效果的Meta分析
- Author:
Rui ZHANG
1
,
2
;
Yu ZHENG
3
,
4
;
Guangdong HOU
3
;
Jixue GAO
5
;
Fuli WANG
3
Author Information
1. Medical College of Yan’an University, Yan’an 716000
2. Department of Urology, First Affiliated Hospital, Air Force Medical University, Xi’an 710032
3. Department of Urology, First Affiliated Hospital, Air Force Medical University, Xi’an 710032
4. Military Medical Innovation Center, Air Force Medical University, Xi’an 710032
5. Department of Urology, Affiliated Hospital of Yan’an University, Yan’an 716000, China
- Publication Type:Journal Article
- Keywords:
non-clear cell renal cell carcinoma;
targeted therapy;
adverse reactions;
metastatic nccRCC;
sunitinib;
cabozantinib
- From:
Journal of Modern Urology
2023;28(5):394-403
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To systematically evaluate the efficacy and safety of targeted drugs in the treatment of metastatic non-clear cell renal cell carcinoma (nccRCC) and to provide guidance for clinical treatment. 【Methods】 All observational studies and randomized controlled trials (RCTs) of nccRCC treated with targeted drugs were retrieved from the PubMed, Embase, the Cochrane Library and Web of Science. Three independent investigators screened the literature, extracted data and evaluated the quality of literature. The RCTs were evaluated using the Cochrane Handbook. One research with insufficient outcome data (follow-up bias) was assessed as high risk, and the other studies showed low or uncertain risk. The non-RCTs were evaluated with the JBI Quality Assessment Tool, and all studies displayed a low risk of bias. The data were analyzed with Stata 17.0 software. 【Results】 A total of 16 studies involving 989 patients were included. Meta-analysis showed that the objective response rate (ORR) was 12.6% (95%CI:8.1%-17.9%), the total disease control rate (DCR) was 65.3% (95%CI:58.3%-72.1%), the total median progression-free survival (PFS) was 5.80 (95%CI:4.69-6.91) months, and the median overall survival (OS) was 15.93 (95%CI:12.17-19.68) months. In subgroup analysis, the total ORR of patients with metastatic nccRCC treated with sunitinib and cabozantinib were 11.7% (95%CI:6.5%-18.0%) and 17.2% (95%CI:8.4%-28.2%), respectively. The total ORR of patients with papillary renal cell carcinoma was 9.1% (95%CI:2.4%-18.9%). 【Conclusion】 Targeted drugs have a significant effect on patients with metastatic nccRCC, but adverse reactions may occur. Targeted drugs have poor effects on metastatic papillary renal cell carcinoma, and cabozantinib may have greater survival benefits.
